Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review

Rheumatology International

Volumn 38, Issue 2, 2018, Pages 293-301

  Borges, Isabela Bruna Pires ^a   Silva, Marilda Guimarães ^a   Misse, Rafael Giovane ^a   Shinjo, Samuel Katsuyuki ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dermatomyositis; Fibrates; Myositis; Polymyositis; Statins

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTILIPEMIC AGENT; ATENOLOL; AUTOANTIBODY; AZATHIOPRINE; BEZAFIBRATE; CHLORTALIDONE; CLONIDINE; CLOPIDOGREL; CREATINE KINASE MM; CYCLOSPORINE; ENALAPRIL; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE ANTIBODY; IMMUNOGLOBULIN; ISOSORBIDE; LEVOTHYROXINE; METFORMIN; METHOTREXATE; METHYLPREDNISOLONE; OMEPRAZOLE; PROPRANOLOL; RITUXIMAB; SIMVASTATIN; SRP AUTOANTIBODY; UNCLASSIFIED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ADD ON THERAPY; ADULT; AGED; ARTHROPATHY; BICEPS BRACHII MUSCLE; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DEATH; DERMATOMYOSITIS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG PULSE THERAPY; DYSPHAGIA; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIMB WEAKNESS; LUNG COMPLICATION; LUNG INFECTION; LYMPHOMA; MALE; MEDLINE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; MUSCLE BIOPSY; NORMAL VALUE; POLYMYOSITIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RECURRENT DISEASE; RELAPSE; REMISSION; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; REVIEW; SEPTIC SHOCK; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; VASTUS LATERALIS MUSCLE; CHEMICALLY INDUCED; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BEZAFIBRATE; DERMATOMYOSITIS; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYMYOSITIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 85031401120     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-017-3821-3     Document Type: Review

References (41)

1. Dalakas MC (2010) Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 10:346–352
2. Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372:1734–1747
3. Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 373:393–394
4. Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325:1487–1498
5. Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971–982
6. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347
7. Plotz PH, Dalakas M, Leff RL, Love LA, Miller FW, Cronin ME (1989) Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med 111:143–157
8. Nagaraju K, Plotz PH, Miller FW (2003) Inflammatory muscle disease: etiology and pathogenesis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology. Elsevier, Toronto, pp 1523–1535
9. Padala S, Thompson PD (2012) Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis 222:15–21
10. Bruckert E, Hayem G, Dejager S, Yau C, Biegaud B (2005) Mild to moderate muscular symptoms with high-dose statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther 19:403–414
11. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH (2005) Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 165:2671–2676
12. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, MastagliA FL (2007) Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 17:194–200
13. Mammen AL, Chung T, Christopher-Stine L et al (2011) Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63:713–721
14. Musset L, Allenbach Y, Benveniste O, Boyer O, Bossuyt X, Bentow C et al (2016) Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study. Autoimmun Rev 15:983–993
15. Pinal-Fernandez I, Mammen AL (2016) Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr Opin Rheumatol 28:619–624
16. Basharat P, Lahouti AH, Paik JJ et al (2016) Statin-induced anti-HMGCR-associated myopathy. J Am Coll Cardiol 68:234–235
17. Mohassel P, Mammen AL (2013) Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve 48:477–483
18. Schalke BB, Schmidt B, Toyka K, Hartung HP (1992) Pravastatin-associated inflammatory myopathy. N Engl J Med 327:649–650
19. Khattak FH, Morris IM, Branford WA (1994) Simvastatin-associated dermatomyositis. Br J Rheumatol 33:199
20. Hill C, Zeitz C, Kirkham B (1995) Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med 25:745–746
21. Rodriguez-Garcia JL, Serrano Commino M (1996) Lovastatin-associated dermatomyositis. Postgrad Med J 72:694
22. Giodarno N, Senesi M, Mattiig Battisti E, Villanova M, Gennari C (1997) Polymyositis associated with simvastatin. Lancet 349:1600–1601
23. Noël B, Cerottini JP, Panizzon RG (2001) Atorvastatin-induced dermatomyositis. Am J Med 110:670–671
24. Riesco-Eizaguirre G, Arpa-Gutiérrez FJ, Gutiérrez M, Toribio E (2003) Severe polymyositis with simvastatin use. Rev Neurol 37:934–936
25. Vasconcelos OM, Campbell WW (2004) Dermatomyositis-like syndrome and HMGCoA reductase inhibitor (statin) intake. Muscle Nerve 30:803–807
26. Takagi A, Shiio Y (2004) Pravastatin-associated polymyositis, a case report. Rinsho Shinkeigaku 44:25–27
27. Thual N, Penven K, Chevallier JM, Dompmartin A, Leroy D (2005) Fluvastatin-induced dermatomyositis. Ann Dermatol Venereol 132:996–999
28. Zuech P, Pauwels C, Duthoit C et al (2005) Pravastatin-induced dermatomyositis. Rev Med Interne 26:897–902
29. Fauchais AL, Iba BAJ, Maurage P et al (2004) Polymyositis induced or associated with lipid-lowering drugs: five cases. Rev Med Interne 25:294–298
30. Sailler L, Pereira C, Bagheri A et al (2008) Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis 67:614–619
31. Rasch A, Schimmer M, Sander CA (2009) Simvastatin-induced dermatomyositis. Hautarzt 60:489–493
32. Inhoff O, Peitsch WK, Paredes BE, Goerdt S, Goebeler M (2009) Simvastatin-induced amyopathic dermatomyositis. Br J Dermatol 161:206–208
33. Zaraa IR, Labbène I, Mrabet D, Zribi H, Chelly I, Zitouna M et al. (2011) Simvastatin-induced dermatomyositis in a 50-year-old man. BMJ Case Rep
34. Kanth R, Shah MS, Flores RM (2013) Statin-associated polymyositis following omeprazole treatment. Clin Med Res 11:91–95
35. Oztas M, Ugurlu S, Aydin O (2017) Atorvastatin-induced dermatomyositis. Rheumatol Int 37:1217–1219
36. Fania L, Didona D, Tonanzi T, Mazzanti C, Didona B (2017) Simvastatin-associated dermatomyositis. Dermatol Ther 30. doi:10.1111/dth.12480
37. Medical Research Council (1943) Aids to the investigation of peripheral nerve injuries. War memorandum n. 7, 2 ed. Her Majesty’s Stationery Office, London
38. Stenzel W, Goebel HH, Aronica E (2012) Review: immune-mediated necrotising myopathies: a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol 38:632–646
39. Mammen AL (2016) Statin-associated autoimmune myopathy. N Engl J Med 374:664–669
40. Flores-Suárez LF, Morales H, Angeles A, Kraus A (2002) Drug-induced amyopathic dermatomyositis. J Clin Rheumatol 8:50–54
41. Sauvaget F, Piette JC, Herson S, De Gennes C, Duyckaerts C, Godeau P (1991) Fenofibrate induced polymyositis. Rev Med Interne 12:52–54